Rotork plc ( ($GB:ROR) ) just unveiled an update. Rotork plc has announced the purchase of 86,000 ordinary shares as part of its ongoing share ...

Informa PLC has announced an update on its share buyback program, committing a minimum of £350 million for 2025. Recently, the company purchased 168,000 ordinary shares for cancellation, impacting its ...

Siili Solutions Plc announced on 26 May 2025 that the Board of Directors had decided to launch a share repurchase programme. The purpose of the programme was to acquire the company’s own shares to ...

The Board of Directors of Siili Solutions Plc (“Siili” or the “Company”) has resolved to commence the repurchase of the Company’s own shares based on the authorisation granted by the Annual General ...

RELX PLC (the “Company”) announces in compliance with the UK and EU Market Abuse Regulations that it will implement an irrevocable, non-discretionary programme to repurchase its ordinary shares ...

LONDON--(BUSINESS WIRE)--Today the board of directors of Dialog Semiconductor Plc (XETRA: DLG) (the Company), a provider of highly integrated power management, AC/DC power conversion, solid state ...

GETECH, the oil services business specialising in the provision of exploration data and geological exploration studies, announces a further sale of its Global Programmes. GETECH announced in April ...

Q1 2023 Operational and Financial Update, Revised 2023 Capital and Dividend Programme Investor Webinar via Investor Meet Company EASTLEIGH, UK / ACCESSWIRE / June 29, 2023 / i3 Energy plc ...

LONDON, UK / ACCESSWIRE / November 1, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company targeting diseases with a high unmet ...

ABINGDON, OXFORDSHIRE / ACCESSWIRE / December 11, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of ...

LEEDS, England, July 25, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on its oncology programmes.